Mednax (MD) Reports In-Line Q2 EPS; Comps Up 1.8%; Guides Lighter Q3 EPS
Tweet
Share
E-mailGet Alerts MD Hot Sheet
Join SI Premium – FREE
Mednax (NYSE: MD) reported Q2 EPS of $1.15, in-line with the analyst estimate of $1.15. Revenue for the quarter came in at $393.4 million versus the consensus estimate of $394.57 million.
Same-unit revenue growth from reimbursement-related factors was 1.8 percent.
Mednax sees Q3 2011 EPS of $1.15-$1.20, versus the consensus of $1.20.
Same-unit revenue growth from reimbursement-related factors was 1.8 percent.
Mednax sees Q3 2011 EPS of $1.15-$1.20, versus the consensus of $1.20.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
- C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance
- Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
